ARIA with edema or effusions (ARIA-E) occurred in 24.4% of donanemab-treated patients in the placebo-controlled trials and 19.8% of donanemab-treated patients in the open-label extension.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback